Skip to main content

ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute Ischemic Stroke

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

via HealthDay

TUESDAY, Feb. 18, 2025 -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days, according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 5 to 7 in Los Angeles.

Min Lou, M.D., Ph.D., from the Second Affiliated Hospital of Zhejiang University School of Medicine in China, and colleagues conducted a prospective, randomized trial at 26 stroke centers in China involving patients with clinical signs of AIS within 4.5 and 24 hours and salvageable tissue on perfusion imaging. Patients were randomly assigned to receive intravenous alteplase or standard medical treatment (186 participants in both groups). The primary outcome was a score of 0 or 1 on the modified Rankin scale at 90 days.

Less than 3 percent of patients underwent endovascular thrombectomy (three and seven in the alteplase and standard medical treatment groups, respectively). The researchers found that the percentage of patients achieving a primary outcome was 40.3 and 26.3 percent in the alteplase and standard medical treatment groups, respectively (relative rate, 1.40; 95 percent confidence interval, 1.05 to 1.87). Mortality at 90 days was 10.8 percent with both alteplase and standard medical treatment, while the incidence of symptomatic intracerebral hemorrhage was 3.8 and 0.5 percent, respectively, within 36 hours after randomization.

"We believe these findings mean more people may return to normal or near-normal lives after a stroke, even if they receive treatment later than originally thought beneficial," Lou said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Brain Age Gap May Mediate Influence of Cognitive Impairment Risk Factors

TUESDAY, June 24, 2025 -- The brain age gap (BAG) plays a role in mediating the influence of cognitive impairment risk factors on cognitive function, especially among individuals...

Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases

THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...

Talking Therapy Reduces Depression, Anxiety Symptoms in Stroke Survivors

THURSDAY, June 12, 2025 -- For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety symptoms, according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.